Immunomonitoring in head and neck cancer patients treated with protein vaccine through tumor destruction
| Project/Area Number |
21592191
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Mie University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YUTA Atsushi 三重大学, 大学院・医学系研究科, リサーチアソシエイト (80293778)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | がんワクチン / 臨床試験 / 免疫モニタリング |
|---|
| Research Abstract |
Immune reactions in head/neck cancer patients treated with protein vaccine, recombinant MAGE-A4 protein complexed with cholesteryl pullulan, were analyzed. 16 subjects including head/neck cancer patients completed 6 or more vaccination. Humoral IgG responses were analyzed with ELISA assay. 3 patients were positive for MAGE-A4 antibody prior vaccination, suggesting that there exists natural positive immunity in MAGE-A4 antigen positive cancer patients. Among them, MAGE-A4 immunity was augmented in one case. In 4 MAGE-A4 antibody negative patients, 2 converted to MAGE-A4 IgG positive. Spreading of immune reactions other than vaccinated antigen was observed.
|
Report
(4 results)
Research Products
(22 results)
-
-
-
[Journal Article] Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia2010
Author(s)
Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, Nagai T, Kishimoto Y, Okada M, Takahashi M, Handa H, Takeuchi J, Kageyama S, Asou N, Yagasaki F, Maeda Y, Ohnishi K, Naoe T
-
Journal Title
JALSG AML95 study Int J Hematol
Volume: 91
Pages: 276-283
Related Report
Peer Reviewed
-
-
[Journal Article] Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia : the JALSG AML95 study2010
Author(s)
Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, Nagai T, Kishimoto Y, Okada M, Takahashi M, Handa H, Takeuchi J, Kageyama S, Asou N, Yagasaki F, Maeda Y, Ohnishi K, Naoe T, Ohno R
-
Journal Title
NAID
Related Report
Peer Reviewed
-
[Journal Article] Antibody responses against NY-ESO-1 and HER2 antigens in patientsvaccinated with combinations of cholesteryl pullulan(CHP)-NY-ESO-1 and CHP-HER2 with OK-4322009
Author(s)
Aoki M, Ueda S, Nishikawa H, Kitano S, Hirayama M, Ikeda H, Toyoda H, Tanaka K, Kanai M, Takabayashi A, Imai H, Shiraishi T, Sato E, Wada H, Nakayama E, Takei Y, Katayama N, Shiku H, Kageyama S
-
Journal Title
Vaccine
Volume: 27
Pages: 6854-6861
Related Report
Peer Reviewed
-
[Journal Article] Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-4322009
Author(s)
Aoki M, Ueda S, Nishikawa H, Kitano S, Hirayama M, Ikeda H, Toyoda H, Tanaka K, Kanai M, Takabayashi A, Imai H, Shiraishi T, Sato E, Wada H, Nakayama E, Takei Y, Katayama N, Shiku H, Kageyama S
-
Journal Title
Vaccine 47
Pages: 6854-6861
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
